DI Hong-Jie, Fan Yao-Fu, Zhang Hui-Feng, Liu Ke-Mian, Liu Chao
Department of Endocrinology, Jiangsu Provincial Hospital of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210028, China.
Zhonghua Nan Ke Xue. 2017 Jun;23(6):517-521.
To evaluate the effects of Testosterone Undecanoate Pills (TUP) on insulin resistance (IR) in type-2 diabetes men with hypogonadism.
We randomly divided 82 type-2 diabetes patients with hypogonadism into a treatment (n = 42) and a control group (n = 40), both maintaining their glucose- and lipid-reducing therapies, while the former treated orally with TUP in addition. After 6 months of medication, we compared the body mass index (BMI), waist circumference (WC), blood glucose level, HbA1c, lipid profile, IR index obtained by homeostatic model assessment (HOMA-IR), insulin sensitivity index (ISI), sex hormone levels, and sexual function scores between the two groups of patients.
Compared with the baseline, the patients in the treatment group showed significant decreases after medication in BMI (［26.71 ± 2.39］ vs ［25.15 ± 2.28］ kg/m2, P <0.05), WC (［89.96 ± 9.13］ vs ［85.03 ± 9.58］ cm, P <0.05), HbA1C (［7.73 ± 1.31］ vs ［7.01 ± 1.25］ %, P <0.05), and triglyeride (［1.97 ± 0.83］ vs ［1.41 ± 0.69］ mmol/L, P <0.05), a markedly elevated level of total testosterone (［7.16 ± 2.21］ vs ［14.22 ± 2.63］ nmol/L, P <0.05), and remarkable improvement in HOMA-IR (3.76 ± 1.18 vs 2.55 ± 1.03, P <0.05), ISI (96 ± 51 vs 138 ± 53, P <0.05) and total scores of the Aging Males' Symptoms (P <0.05). But no significant changes were observed in the scores of the International Index of Erectile Function (IIEF) after treatment (13.28 ± 6.38 vs 14.95 ± 6.08, P >0.05).
TUP can significantly improve insulin resistance in type-2 diabetes men with hypogonadism.
评估十一酸睾酮软胶囊（TUP）对2型糖尿病合并性腺功能减退男性胰岛素抵抗（IR）的影响。
我们将82例2型糖尿病合并性腺功能减退患者随机分为治疗组（n = 42）和对照组（n = 40），两组均维持降糖和降脂治疗，治疗组在此基础上口服TUP。用药6个月后，比较两组患者的体重指数（BMI）、腰围（WC）、血糖水平、糖化血红蛋白（HbA1c）、血脂谱、稳态模型评估法（HOMA-IR）所得的IR指数、胰岛素敏感指数（ISI）、性激素水平及性功能评分。
与基线相比，治疗组患者用药后BMI（［26.71±2.39］ vs ［25.15±2.28］kg/m²，P<0.05）、WC（［89.96±9.13］ vs ［85.03±9.58］cm，P<0.05）、HbA1C（［7.73±1.31］ vs ［7.01±1.25］%，P<0.05）和甘油三酯（［1.97±0.83］ vs ［1.41±0.69］mmol/L，P<0.05）显著降低，总睾酮水平显著升高（［7.16±2.21］ vs ［14.22±2.63］nmol/L，P<0.05），HOMA-IR（3.76±1.18 vs 2.55±1.03，P<0.05）、ISI（96±51 vs 138±53，P<0.05）及老年男性症状总评分显著改善（P<0.05）。但治疗后国际勃起功能指数（IIEF）评分无显著变化（13.28±6.38 vs 14.95±6.08，P>0.05）。
TUP可显著改善2型糖尿病合并性腺功能减退男性的胰岛素抵抗。
Zotero 插件